Advertisement
IONS vs ROIV
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IONS is a Hold and ROIV is a Buy.
IONS's RSI Oscillator climbs out of oversold territory
The RSI Indicator for IONS moved out of oversold territory on October 06, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 26 similar instances when the indicator left oversold territory. In 19 of the 26 cases the stock moved higher. This puts the odds of a move higher at 73%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on IONS as a result. In 73 of 102 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 72%.
The Moving Average Convergence Divergence (MACD) for IONS just turned positive on October 02, 2026. Looking at past instances where IONS's MACD turned positive, the stock continued to rise in 34 of 49 cases over the following month. The odds of a continued upward trend are 69%.
Following a +3.41% 3-day Advance, the price is estimated to grow further. Considering data from situations where IONS advanced for three days, in 190 of 280 cases, the price rose further within the following month. The odds of a continued upward trend are 68%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 38 of 64 cases where IONS's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 59%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IONS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 64%.
The Aroon Indicator for IONS entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 24 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 75 (best 1 - 100 worst), indicating slightly worse than average price growth. IONS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 81 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IONS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron Valuation Rating of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (15.585) is normal, around the industry mean (3.162). P/E Ratio (-11.851) is within average values for comparable stocks, (-1.064). Projected Growth (PEG Ratio) (4.040) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.622) among similar stocks. P/S Ratio (8.368) is also within normal values, averaging (439.647).
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Momentum Indicator for ROIV turns positive, indicating new upward trend
ROIV saw its Momentum Indicator move above the 0 level on October 21, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 92 similar instances where the indicator turned positive. In 77 of the 92 cases, the stock moved higher in the following days. The odds of a move higher are at 84%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ROIV's RSI Oscillator exited the oversold zone, 17 of 24 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 71%.
The Moving Average Convergence Divergence (MACD) for ROIV just turned positive on October 21, 2026. Looking at past instances where ROIV's MACD turned positive, the stock continued to rise in 43 of 57 cases over the following month. The odds of a continued upward trend are 75%.
ROIV moved above its 50-day moving average on October 28, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +2.68% 3-day Advance, the price is estimated to grow further. Considering data from situations where ROIV advanced for three days, in 229 of 295 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
The 10-day moving average for ROIV crossed bearishly below the 50-day moving average on October 05, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ROIV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 70%.
ROIV broke above its upper Bollinger Band on October 21, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for ROIV entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 3 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.301) is normal, around the industry mean (3.162). ROIV has a moderately low P/E Ratio (-102.528) as compared to the industry average of (-1.064). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.622) among similar stocks. ROIV's P/S Ratio (3333.333) is slightly higher than the industry average of (439.647).
The Tickeron Profit vs. Risk Rating rating for this company is 11 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 38 (best 1 - 100 worst), indicating steady price growth. ROIV’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 55 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 92 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
IONS | ROIV | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 85 Overvalued | 3 Undervalued | |
PROFIT vs RISK RATING 1..100 | 81 | 11 | |
SMR RATING 1..100 | 99 | 92 | |
PRICE GROWTH RATING 1..100 | 75 | 38 | |
P/E GROWTH RATING 1..100 | 24 | 55 | |
SEASONALITY SCORE 1..100 | n/a | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ROIV's Valuation (3) in the null industry is significantly better than the same rating for IONS (85) in the Biotechnology industry. This means that ROIV’s stock grew significantly faster than IONS’s over the last 12 months.
ROIV's Profit vs Risk Rating (11) in the null industry is significantly better than the same rating for IONS (81) in the Biotechnology industry. This means that ROIV’s stock grew significantly faster than IONS’s over the last 12 months.
ROIV's SMR Rating (92) in the null industry is in the same range as IONS (99) in the Biotechnology industry. This means that ROIV’s stock grew similarly to IONS’s over the last 12 months.
ROIV's Price Growth Rating (38) in the null industry is somewhat better than the same rating for IONS (75) in the Biotechnology industry. This means that ROIV’s stock grew somewhat faster than IONS’s over the last 12 months.
IONS's P/E Growth Rating (24) in the Biotechnology industry is in the same range as ROIV (55) in the null industry. This means that IONS’s stock grew similarly to ROIV’s over the last 12 months.
| IONS | ROIV | |
|---|---|---|
| RSI ODDS (%) | 4 days ago 73% | 4 days ago 71% |
| Stochastic ODDS (%) | 4 days ago 59% | 4 days ago 74% |
| Momentum ODDS (%) | 4 days ago 72% | 4 days ago 84% |
| MACD ODDS (%) | 4 days ago 69% | 4 days ago 75% |
| TrendWeek ODDS (%) | 4 days ago 72% | 4 days ago 76% |
| TrendMonth ODDS (%) | 4 days ago 66% | 4 days ago 78% |
| Advances ODDS (%) | 6 days ago 68% | 5 days ago 78% |
| Declines ODDS (%) | 4 days ago 64% | 8 days ago 70% |
| BollingerBands ODDS (%) | N/A | 4 days ago 72% |
| Aroon ODDS (%) | 4 days ago 58% | 4 days ago 88% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
IONS’s FA Score shows that 1 FA rating(s) are green while ROIV’s FA Score has 2 green FA rating(s).
- IONS’s FA Score: 1 green, 4 red.
- ROIV’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
IONS’s TA Score shows that 4 TA indicator(s) are bullish while ROIV’s TA Score has 5 bullish TA indicator(s).
- IONS’s TA Score: 4 bullish, 3 bearish.
- ROIV’s TA Score: 5 bullish, 5 bearish.
Price Growth
IONS (@Biotechnology) experienced а +1.37% price change this week, while ROIV (@Biotechnology) price change was +1.15% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -0.43%. For the same industry, the average monthly price growth was -12.73%, and the average quarterly price growth was -19.68%.
Reported Earning Dates
IONS is expected to report earnings on Nov 04, 2026.
ROIV is expected to report earnings on Nov 09, 2026.
Industries' Descriptions
@Biotechnology (-0.43% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
IONS and
Correlation & Price change
A.I.dvisor indicates that over the last year, IONS has been loosely correlated with ARWR. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if IONS jumps, then ARWR could also see price increases.
| Ticker / NAME | Correlation To IONS | 1D Price Change % | ||
|---|---|---|---|---|
| IONS | 100% | -1.96% | ||
| ARWR - IONS | 43% Loosely correlated | -0.98% | ||
| AXON - IONS | 43% Loosely correlated | -2.35% | ||
| TARS - IONS | 41% Loosely correlated | +0.88% | ||
| CRSP - IONS | 38% Loosely correlated | -5.23% | ||
| BEAM - IONS | 37% Loosely correlated | -5.58% | ||
More | ||||
ROIV and
Correlation & Price change
A.I.dvisor indicates that over the last year, ROIV has been loosely correlated with IMVT. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if ROIV jumps, then IMVT could also see price increases.
| Ticker / NAME | Correlation To ROIV | 1D Price Change % | ||
|---|---|---|---|---|
| ROIV | 100% | -1.63% | ||
| IMVT - ROIV | 63% Loosely correlated | -1.59% | ||
| IMTX - ROIV | 44% Loosely correlated | -1.50% | ||
| AXON - ROIV | 43% Loosely correlated | -2.35% | ||
| DNTH - ROIV | 42% Loosely correlated | -0.39% | ||
| MLYS - ROIV | 41% Loosely correlated | -14.41% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| IXG | 129.19 | -1.44 | -1.10% |
| iShares Global Financials ETF (IXG) | |||
| XBI | 155.98 | -1.81 | -1.15% |
| State Street SPDR S&P Biotech ETF (XBI) | |||
| JPAN | 41.37 | -0.74 | -1.76% |
| Matthews Japan Active ETF (JPAN) | |||
| NZAC | 45.54 | -0.83 | -1.79% |
| State Street SPDR MSCI ACWI Climate Paris Aligned ETF (NZAC) | |||
| RDTL | 3.63 | -5.23 | -59.03% |
| GraniteShares 2x Long RDDT Daily ETF (RDTL) | |||